Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Wednesday

Sanara MedTech (NASDAQ:SMTI) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Sanara MedTech to post earnings of ($0.33) per share and revenue of $25.15 million for the quarter.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 12.48% and a negative return on equity of 29.22%. The business had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Stock Performance

NASDAQ SMTI opened at $24.80 on Monday. The company has a market capitalization of $220.47 million, a PE ratio of -18.51 and a beta of 1.26. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.54 and a current ratio of 2.77. The company has a 50-day simple moving average of $27.66 and a 200 day simple moving average of $30.68. Sanara MedTech has a 52-week low of $23.53 and a 52-week high of $39.08.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on shares of Sanara MedTech from $51.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, May 15th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sanara MedTech stock. Rhumbline Advisers lifted its holdings in Sanara MedTech Inc. (NASDAQ:SMTI) by 14.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,714 shares of the company’s stock after buying an additional 483 shares during the quarter. Rhumbline Advisers’ holdings in Sanara MedTech were worth $115,000 as of its most recent SEC filing. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.